For diabetes, patches instead of injections? Wroclaw-based Biotts has filed a new patent in the US

12.02.2024

Biotts, a biopharmaceutical company based in Wroclaw, has filed a patent application in the United States. It intends to help patients treat diabetes and obesity by replacing injections with patches. The finished product is expected to be on the market by 2027 at the latest. It's also a big chance for financial success, as the market for such medical products will be worth $100 billion a year by 2030.

Biotts is a Wroclaw-based company that was the first in the world to successfully administer semaglutide, a drug used in diabetes, through the skin, in addition, obtaining 10 times higher results in the bioavailability of the drug’s active substances compared to the oral form.

Besides, this way of its administration contributes to the reduction of negative side effects that occur with tablets and injections. Biotech’s transdermal system can be used for the application of commonly used anti-diabetic, oncology, anti-inflammatory and analgesic drugs.

Product tested on humans

Currently, the company has successfully completed human clinical trials testing MTC-Y carriers with the anti-diabetic substance dapagliflozin. The project confirmed the safety and effectiveness of the carrier, allowing the transdermal patches to be tested with another anti-diabetic substance – active insulin. This opens the floodgates for further carrier testing with insulin from Bioton SA. Biotts plans to launch the finished product on the global pharmaceutical market by 2027 at the latest. Experts estimate that the market for such drugs will reach $100 billion a year by 2030.

According to Jan Hendriks, president of Biotts, the company’s specialists are working on the formulation all the time, and it is possible that their target product will have even greater bioavailability.

Biotts has just filed a patent application for transdermal semaglutide and other GLP-1 molecules in the US, and plans to bring the finished product to market by the end of 2026.

Patients don’t like injections

Recent analyses confirm patients’ preference for replacing insulin injections with an unconventional, non-invasive method. They are constantly looking for modern solutions that will not only help them with self-treatment and ensure the comfort and safety of daily treatment, but also give them the feeling that they can function like healthy people. Hence the effectiveness of Biotts transdermal carrier, i.e. the increased efficiency of transporting active substances through the skin into the bloodstream, without unwanted side effects.